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Background: Fluid removal during dialysis, also known as ultrafiltration (UF), leads to intradialytic hypotension (IDH)
in a significant number of patients treated with hemodialysis (HD) and is associated with an increase in morbidity
and mortality. At present, there are no accepted standards of practice for the prevention or treatment of IDH.
Relative blood volume monitoring (BVM) is based on the concept that the hematocrit increases with UF, relative to
the patient’s baseline hematocrit. The use of BVM biofeedback, whereby the HD machine automatically adjusts the
rate of UF based on the relative blood volume, has been proposed for the prevention of IDH.
Methods/Design: This is a 22-week randomized crossover trial. Participants undergo a 4-week run-in phase to
standardize medications and dialysis prescriptions. Subsequently, participants are randomized to standard HD or to
BVM biofeedback for a period of 8 weeks followed by a 2-week washout phase before crossing over. The dialysis
prescription remains identical for both arms. The primary outcome is the frequency of symptomatic IDH as defined
by an abrupt drop in the systolic blood pressure of ≥20 mm Hg accompanied by headache, dizziness, loss of consciousness,
thirst, dyspnea, angina, muscle cramps or vomiting. Secondary outcomes include the number of symptomatic IDH episodes
and any reduction in IDH episodes, nursing interventions, dialysis adequacy, total body water, extra- and intracellular fluid
volumes, brain natriuretic peptide and cardiac troponin levels, blood pressure, antihypertensive medication use, patient
symptoms and quality of life.
Discussion: Our study will determine the impact of using BVM biofeedback to prevent IDH and other serious adverse
events in susceptible patients.
Trial registration: Clinicaltrials.gov NCT01988181 (6 November 2013).
Keywords: Hemodialysis, Blood volume monitoring biofeedback, Intradialytic hypotension, Randomized crossover trialBackground
The majority of patients with end-stage renal disease are
treated with hemodialysis (HD) to regulate their fluid
balance and other native kidney functions [1,2]. Patients
treated with HD have a 5-year mortality rate of 57%,
with the majority of deaths due to cardiac and infectious
causes [3,4]. A growing body of literature has emerged
linking chronic fluid overload in HD to hypertension,
left ventricular hypertrophy and increased all-cause* Correspondence: kcwleung@ucalgary.ca
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unless otherwise stated.mortality [5-7]. To prevent volume overload and main-
tain fluid balance, 1 to 5 L of fluid must be removed
during each HD treatment.
Rapid fluid removal, or ultrafiltration (UF), during a
short period of time can lead to intradialytic hypotension
(IDH) in as many as 25% to 50% of patients treated with
HD [8]. IDH is most commonly defined as an abrupt drop
in systolic blood pressure of ≥20 mm Hg accompanied by
symptoms of cerebral, cardiac, gastrointestinal or muscu-
loskeletal ischemia [9-11]. Observational studies haveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pressure is associated with an increase in morbidity and
mortality [12-20].
UF during HD leads to a fall in the patient’s blood vol-
ume. The blood volume can be measured by tracking
the changes in hemoglobin or protein concentration at
the arterial port during dialysis using optical photometry
or ultrasound [21-28]. In clinical studies, higher rates of
UF lead to faster declines in the relative blood volume
and as a result, a steeper decline in the blood volume
monitoring (BVM) curves [27-29]. BVM-guided biofeed-
back is based on the principle that the relative blood
volume (compared to baseline) appears to decrease more
rapidly in sessions complicated by IDH [25,30]. As a
result, BVM-guided UF biofeedback, whereby the dia-
lysis machine automatically reduces the rate of UF
prior to reaching the patient’s critical blood volume,
has been proposed for the prevention of IDH and its
sequelae [22,23,31-34].
We will conduct a randomized controlled clinical trial
to test whether biofeedback incorporating BVM-guided
UF adjustments alone (without adjustment of the dialys-
ate sodium concentration), in addition to best clinical
practice, results in a reduction in the frequency of symp-
tomatic IDH episodes and patient symptoms compared
to best clinical practice alone. Secondary outcomes include
the frequency of IDH-related interventions, dialysis-related
symptoms, dialysis adequacy, volume control, biomarkers




This is a 22-week parallel-group randomized crossover
trial. During the first part of the study, the run-in and
dialysis optimization phase, eligible participants will undergo
a 4-week run-in. During this period, all participants will
undergo a comprehensive clinical assessment including a
clinical weight assessment, an antihypertensive medication
review and standardization of their dialysis prescription. At
the end of the run-in phase, participants that still meet the
eligibility criteria will enter part 2, the randomized crossover
phase. In this phase, the participants are randomized to
regular best clinical practice HD (without BVM-guided UF
biofeedback; the control arm) or to best clinical practice plus
BVM-guided UF biofeedback (the intervention arm) for an
8-week period. This will be followed by a 2-week washout
phase and then the participants will be crossed over for a
second 8-week phase. The participant flow chart and time-
line are shown in Figure 1. The study will be conducted and
reported following the Consolidated Standards of Reporting
Trials (CONSORT) 2010 guidelines [35]. The study protocol
was approved by the University of Calgary Conjoint Health
Research Ethics Board (ethics ID: REB13-1139).Study setting
The clinical trial will be held at two tertiary care units
(Foothills Medical Centre and Peter Lougheed Centre)
and three community HD units (Fanning Centre, Sheldon
Chumir Centre and Sunridge Centre) in the Southern
Alberta Renal Program, Calgary, Alberta, Canada.
Study participants
All participants who have been treated with HD for
more than 3 months will be screened for eligibility. To
be eligible for the study, participants must be >18 years
of age, medically stable, undergo HD three to four times
per week for a minimum of 3 hours per session, and
have had >30% of their HD sessions in the preceding
8 weeks complicated by symptomatic IDH. Participants with
serum sodium ≤133 mmol/L [36], hemoglobin <80 g/L,
active malignancy, a history of blood transfusion or
hospitalization in the preceding 4 weeks, routine use
of diuretics for volume management, a history of on-
going urine output estimated at greater than or equal
to 250 mL (one cup) per day, or a planned change in
the renal replacement modality during the study period
will be excluded. Informed consent will be obtained from
each individual who agrees to participate in the study.
Definition of symptomatic intradialytic hypotension
Symptomatic IDH is defined as a drop in systolic blood
pressure of ≥20 mm Hg from baseline with associated
symptoms [9,10]. Symptoms include sudden-onset head-
ache, dizziness, unconsciousness, thirst, dyspnea, angina,
muscle cramps and vomiting [10,11].
Interventions
Part 1: run-in phase
Following enrollment, participants will undergo a 4-week
run-in phase to optimize their dialysis weight and dialysis
prescriptions, and to determine the critical relative blood
volume values (BVM will be enabled). During the first
2 weeks of the run-in phase, participants will undergo a
medication review and dry-weight reduction based on a
modified protocol from the Dry-Weight Reduction In
Hypertensive Hemodialysis Patient (DRIP) trial [37,38].
Part 2: crossover study phase
Participants that continue to have more than 30% of
their sessions complicated by symptomatic IDH during
the run-in phase are randomized to either 8 weeks of
best clinical practice (without BVM or biofeedback; con-
trol) or best clinical practice plus BVM-guided UF bio-
feedback (intervention), followed by a 2-week washout
period (using the control phase HD prescription) before
crossing over to the other study arm for a second 8-week
block. Participants will have clinical assessments of their
dry weight at the beginning of each week.
Figure 1 Participant flow diagram. HD, hemodialysis; IDH, intradialytic hypotension.
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All study participants will be dialyzed with the Fresenius
5008 HD machine (Fresenius Medical Care, Bad Homburg,
Germany) using high-flux dialyzers. Participants in the best
clinical practice (control) group will use the same prescrip-
tion used during the run-in phase: dialysate sodium of
138 mmol/L, dialysate calcium of 1.25 mmol/L, dialysatetemperature of 36°C and constant UF rate. BVM will be
disabled in this group.
Intervention group
Participants in the BVM-guided UF biofeedback group
will have the same prescription as the control group, but
will also have the UF rate automatically adjusted by the
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blood volume.Ultrafiltration biofeedback guided by blood volume
monitoring using the Fresenius 5008
The Fresenius 5008 uses an ultrasound monitor incorpo-
rated into the machine to detect ultrasonic velocity changes
to derive the total protein concentration, which is a sum of
total plasma proteins and hemoglobin. A temperature moni-
tor is also incorporated to correct for temperature-related
changes in ultrasound velocity [21,39]. Since the total pro-
tein does not change, any changes in its concentration are
attributed to blood volume changes (Figure 2). The relative
blood volume is calculated by dividing the initial concentra-
tion of total protein by the total protein concentration
at any given time, multiplied by 100 [21]. This method
for measuring relative blood volume has been previously
validated with both optical and laboratory hemoglobin
techniques [21,24].
The HD software in the Fresenius 5008 HD machine
adjusts the UF rate based on the critical blood volume
entered at the beginning of the dialysis session for each
individual patient. There is no adjustment to the dialys-
ate sodium concentration. To determine the actual UF
rate, the HD software first calculates the maximum UF
rate. The maximum UF rate is 2 times the total UF di-
vided by the remaining time. The actual UF rate is the
maximum UF rate multiplied by the UF coefficient,
which is a number between zero and one. To allow for
the maximum UF at the onset of HD, the UF coefficient
is one at the start of HD and continues to remain at one
until the relative blood volume is halfway towards the
critical relative blood volume. At the halfway point be-
tween the start and the critical relative blood volume,
the UF coefficient decreases linearly. Once the critical
relative blood volume is reached, the UF coefficient be-
comes zero, resulting in cessation of UF [21,24,40].Figure 2 Depiction of blood volume monitoring (BVM) profile
and the corresponding ultrafiltration profile.Determination of critical blood volume
There is currently no standardized method for determin-
ing the critical relative blood volume. To standardize
this process, a single investigator (KL) will use the fol-
lowing method/algorithm:
1. Identify the most recent episode of symptomatic
IDH as per the study definition.
2. The critical blood volume will be equal to the
relative blood volume recorded immediately prior to
the episode of symptomatic IDH.
3. The critical blood volume will be reassessed weekly.
Weight adjustments
Each week participants will have their target weight assessed
by a single study investigator (KL). The rounding dialysis
physician will be encouraged to discuss any weight adjust-
ments with study personnel.
Responding to episodes of intradialytic hypotension
In the event that an IDH episode occurs, the bedside
dialysis nurse will follow a predefined IDH algorithm
(Additional file 1) [38]. Following resolution of an IDH
episode as defined in the primary outcome section, UF
will resume. In the control group, a constant UF rate
will be reset to meet the UF goal. In the intervention
group, BVM-guided UF biofeedback will be re-enabled.
Outcomes
Primary outcome
The primary outcome is the rate of symptomatic IDH.
The number of symptomatic IDH episodes along with
the duration of each dialysis treatment will be captured.
The rate of IDH for each session will be calculated by
dividing the number of episodes by the duration of the
session in hours. The rate of IDH will be calculated for
every dialysis treatment. The rate of symptomatic IDH
will be measured in the 2 months preceding enrolment
and during each phase of the study. By using the rate of
symptomatic IDH, rather than the frequency or number
of IDH episodes per session as done in previous studies,
we will be more sensitive to meaningful changes in IDH
episodes as multiple episodes of symptomatic IDH can
occur over various durations of dialysis [31,32,41].
Secondary outcomes
The secondary outcomes of interest are the number and
frequency of nursing interventions, the number and fre-
quency of both symptomatic and asymptomatic IDH,
the number and frequency of dialysis symptoms, dialysis
adequacy as measured by single-session Kt/V, total body
water, extracellular fluid volume (ECFV), intracellular fluid
volume (ICFV), the ECFV:ICFV ratio as determined by
electrical bioimpedance, changes in brain natriuretic
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troponin level, changes in blood pressure (mean arter-
ial pressure pre-, intra- and post-dialysis), changes in
antihypertensive medications, changes in the BVM curves,
intradialytic and interdialytic symptom survey, and nurs-
ing satisfaction.
IDH-related nursing interventions are defined as the use
of the Trendelenburg/supine position, discontinuation of
UF, fluid/saline challenge, return of blood, shortened
dialysis run, or a prolonged (more than 15 minutes)
post-dialysis recovery period as a result of IDH or its
symptoms. Given the subjective nature of IDH-related
symptoms and intervention, in-services and custom-
ized dialysis run sheets will be provided to all nurses at
participating dialysis centers to ensure that all events
are recorded, and recorded consistently.
Dialysis adequacy, measured by single-pool Kt/V, will be
measured and recorded (usual care) at the end of each
dialysis session on the session sheet. Single-pool Kt/V will
be calculated using the previously validated, online clear-
ance measurement method, which detects changes in con-
ductivity in the dialysate to reflect the clearance of serum
electrolytes and urea [42].
Whole body and segmental bioimpedance analysis has
been validated for the determination of fluid compos-
ition in HD patients [43-47]. Electrical bioimpedance
will be performed during the mid-week HD session of
weeks 1, 4, 8, 12, 14, 18 and 22 of the study to determine
the total body water, ECFV and ICFV levels and the
ECFV:ICFV ratio.
Biomarkers of cardiac stress, serum BNP and high-
sensitivity cardiac troponin levels as well as the number and
class of antihypertensive medications used will be recorded
at the mid-week HD session of weeks 1, 4, 12, 14 and 22 of
the study. Diuretic use will not be recorded as participants
with significant residual renal function are excluded.
Two types of survey will be administered and com-
pleted by the patient alone, or with the aid of the dialysis
nurse. The first, provided at the beginning of each dialy-
sis session, is a validated survey inquiring about the time
it took the patient to recover to baseline following a previ-
ous dialysis session (interdialytic period) [48]. The second,
provided at the end of each dialysis session, inquires about
intradialytic symptoms of IDH, specifically nausea, vomit-
ing, chest pain, shortness of breath, headache, muscle
cramps, dizziness, fainting, fatigue and anxiety. A survey
inquiring about nursing perception and attitudes of the
BVM-guided UF biofeedback will be provided to the
nurses at the end of the control and intervention phases.
Sample size calculation
We have previously estimated that 23% of our HD popu-
lation have IDH [38]. To estimate the sample size, we
conservatively assumed that only one IDH episode wouldoccur per run (although it is likely that more than one epi-
sode will occur per run, increasing the study power). With
this approach, and using a 2 × 2 crossover design, we esti-
mated that a sample size of 30 participants would provide
a power of 90% to demonstrate a 30% reduction in the
rate of IDH under the biofeedback treatment vs. the con-
trol treatment, with a two-sided alpha of 0.05. We will en-
roll 34 participants to guard against dropout, which can
be as high as 30% [41]. These estimates are based on
simulation studies assuming only one IDH episode per
run and two Poisson processes with average rates of
IDH equal to 7 (control) and 5 (intervention) episodes
over 24 runs. We used R (R Foundation for Statistical
Computing, Vienna, Austria) [49] for simulations, and
the package clusterPower in R.
Recruitment
Recruitment will take place sequentially at the four par-
ticipating HD units. From pilot data, we anticipate that
approximately 20% of the 400 HD patients in participat-
ing units will meet the criteria for IDH [38] and at least
half of the eligible participants (40 participants) will be
willing to participate in our study [50,51].
Assignment of intervention, allocation concealment
mechanism and implementation
Randomization of allocation sequence will be done using
computer-generated random numbers under the super-
vision of a statistician in the Department of Medicine,
University of Calgary. Subsequently, the allocation sequence
will be inserted into sequentially numbered, opaque, sealed
envelopes. Following study consent and enrollment, an en-
velope containing the allocation sequence will be provided
to the patient’s HD nurse, who will implement the interven-
tion according to the protocol.
Blinding
Given the nature of our intervention, and the inability to
disable the BVM-guided UF biofeedback screens, prompts
and alarms, we will not be able to blind the study
personnel (KL) or the bedside dialysis nurse. The trial par-
ticipants will be blinded to the intervention. To reduce
bias, the HD nurse will be encouraged to document all
intradialytic symptoms and interventions, as well as not to
reveal the allocation sequence to the trial participant. In
addition, study personnel (KL) will assess target weights
and administer surveys uniformly. Study personnel in-
volved with data abstraction and analysis will be blinded
to the study intervention.
Data collection
Collection of baseline and run-in phase data
Baseline patient demographics (age, gender, HD vintage
and race), comorbidities (e.g. congestive heart failure,
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of renal disease, medications (number and class of antihy-
pertensive), laboratory investigations (e.g. serum electro-
lytes, complete blood count and albumin), HD prescription
(dialyzer type, composition, temperature, blood and dialys-
ate flow rates, target weight, anticoagulation, use of sodium
and/or UF profiles), and number of episodes of IDH over
the preceding 8 weeks and run-in phase will be extracted
from HD charts and local electronic health records by the
study investigator.Collection of primary outcome variables
Both sitting and standing blood pressure will be measured
in a standardized fashion at the beginning and end of each
dialysis session [52,53]. Intradialytic blood pressures will
be measured in a sitting position every 30 minutes and at
the time of IDH-related symptoms as defined in the out-
comes section. Sitting blood pressures will be measured
with the patient seated with their feet flat on the floor or a
foot rest, back against a chair with a bare arm resting on a
support, whereby the midpoint of the upper arm is at the
level of the heart. Standing blood pressures will be mea-
sured with the patient standing feet flat on the floor, with
a bare arm resting on a support, whereby the midpoint of
the upper arm is at the level of the heart. An appropriate-
sized blood pressure cuff, where the cuff bladder length is
80% of the arm circumference, will be used. Blood pres-
sure taken while the patient is in a Trendelenburg or su-
pine position will be accepted if the patient is unable to sit
during the pre-specified blood pressure measurement or
is experiencing IDH-related symptoms. All blood pres-
sures will be measured using an automated cuff at-
tached to the dialysis machine. Manual blood pressure
will be accepted if an automated blood pressure meas-




Mid-week 1 Mid-week 4
Hemodialysis run sheet X Randomization
Kt/V X













Medication review X Xof measurement, patient position, IDH-related symp-
toms and nursing interventions will be recorded by the
bedside dialysis nurse.
Collection of secondary outcome variables
Dialysis adequacy, bioimpedance, BNP, high-sensitivity
cardiac troponin, intra- and interdialytic symptom sur-
vey and antihypertensive medication use will be col-
lected by study personnel at the pre-specified times
(Table 1).
Participant retention and follow-up
Following enrollment, every effort will be made to follow
up participants until the end of the study phase. Partici-
pants moving to different dialysis sites across the city of
Calgary will be followed unless they move to a site not
using the Fresenius 5008 machines, at which point they
will be censored. Participants who move out of the city
will be censored.
Statistical analysis
We will use mixed-effects Poisson regression to test the
null hypothesis that the ratio of the rate of IDH episodes
(main model exposure) during the intervention phase
over the rate of IDH episodes during the control phase
will range between 0.7 and 1.3 (i.e., the alternative two-
sided hypothesis is that the incidence rate ratio will be
0.7 or lower). We will study the effect of the interven-
tion as a fixed effect and account for the correlation in
the data due to the subject using random effects. The
multi-level model will have errors due to within-subject
variation and due to between-cluster variation (between
subject variance). In the event that the study generates
over-dispersed data, we will use a negative binomial re-
gression with the approach as described above. We willPart 2 Part 2
Mid-week 8 Mid-week 12 Mid-week 18 Mid-week 22
Crossover and
washout
X X X X
X X X X
X X X X
X X X X
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systolic blood pressure (>30 mmHg) benefit from the
planned intervention. They will be analyzed as a subgroup.
Ethics
Ethical approval has been granted from the University of
Calgary Research Ethics Board. The research coordinator
will determine patient eligibility, obtain consent from
participants for participation in the study and access the
sealed envelope containing allocation details. The coord-
inator will obtain the HD run sheets and submit them to
an independent data entry clerk who is blinded to alloca-
tion. All data are kept strictly confidential. The principal
investigator (JM) and study personnel (KL) are respon-
sible for coordination of the study. The trial is registered
with Clinicaltrials.gov (NCT01988181).
Discussion
Randomized studies assessing the role of BVM and
BVM-guided UF biofeedback in the prevention of IDH
are limited and of low quality. One the largest studies
assessing BVM without biofeedback, which was done by
Reddan et al., randomized 443 participants to BVM or
conventional HD over a 6-month period. Participants in
the BVM group had UF rates adjusted at the discretion
of the bedside dialysis nurse with a suggested UF algo-
rithm. Due to the need for manual adjustment of the UF
rate, it is unclear if the nurses promptly responded to
changes in relative blood volume using the suggested al-
gorithm. In fact, the participants randomized to BVM
had increased hospitalization and mortality, which may
have reflected a lack of adherence to the UF algorithm,
or alternatively could have been related to more cautious
fluid removal due to the feedback provided by the BVM
device [33].
However, when BVM is combined with biofeedback
there may be a beneficial reduction in IDH and blood
pressure [31,32,41,54]. In a 16-week randomized cross-
over study by Dasselaar et al., 28 hypertensive patients
were randomized to either BVM-guided UF and sodium
biofeedback or standard HD for blood pressure and vol-
ume control. Despite a significant reduction in blood
pressure of 22.5/8.3 mm Hg in the BVM group and
extracellular water to body volume ratios when com-
pared to the standard HD group, the overall weight did
not change. Although the values were not reported, this
study also found a statistically significant reduction in
dialysis hypotension [54]. A recent meta-analysis of six
studies using BVM-guided biofeedback reported a 39%
overall reduction in the number of dialysis sessions com-
plicated by IDH [55]. Of the six studies assessing IDH,
three did not have IDH as the primary outcome. Five
studies employed an intervention that included both di-
alysate sodium and UF biofeedback [31,34,56-58]. Thecombination of dialysate sodium and UF biofeedback
over UF biofeedback alone raises concerns regarding the
potential for sodium loading and resultant interdialytic
weight gain through increased plasma osmolality and
thirst, perpetuating the vicious cycle of IDH. In addition,
the duration of the intervention phase in these studies
ranged from 2 weeks to 6 months, with the majority
using a short 2- to 4-week intervention, putting the
long-term sustainability of the intervention into ques-
tion. Three did not have a washout period between the
intervention and control groups, and one did not have a
run-in phase. The majority of the studies did not assess
for changes in body fluid composition, nor did they address
patient quality of life. In addition, the available studies are
generally of low quality due to unclear randomization, un-
clear exclusion criteria and the inclusion of low numbers of
IDH-prone participants [55].
Only one randomized crossover study (26 HD partici-
pants) examined the impact of BVM-guided UF biofeed-
back on patient symptoms during dialysis. The primary
outcome was the percentage reduction in dialysis symp-
toms, which was 8%. The secondary outcome was a reduc-
tion in hypotension [41]. The trial has several weaknesses
including short duration (6 weeks), a lack of a washout
period, a nonstandard definition of IDH and potential bias
due to its industry-funded nature.
Currently, a prospective multi-center triple-arm parallel-
group crossover randomized controlled trial is in progress.
It is comparing BVM-guided UF biofeedback and blood
thermal monitoring temperature biofeedback, to BVM-
guided UF and sodium biofeedback, and to standard HD
in fluid overloaded HD patients. The primary outcome in
this study is the proportion of HD sessions that were com-
plicated with intra- and post-dialytic symptoms related to
UF, irrespective of blood pressure. The secondary out-
comes include both symptomatic and asymptomatic IDH,
using a non-standard definition of a >40 mm Hg drop in
systolic blood pressure [59]. In contrast, our study focuses
on enrolling symptomatic IDH patients, a standard IDH
definition of ≥20 mm Hg, and studying only BVM-guided
UF biofeedback without another accompanying biofeed-
back technology.
We have described our methods for recruitment,
randomization, allocation concealment, dialysis inter-
vention, outcome assessment and data collection methods
in detail. The study protocol was developed according to
the Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) 2013 [60]. It will be conducted
and the results reported following the Consolidated Stan-
dards of Reporting Trials (CONSORT) statement [35].
Trial status
Enrollment began in June 2014 with an expected com-
pletion date of July 2015.
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Additional file 1: Nursing IDH Management Algorithm. This is the
current local protocol for management of IDH that will be followed by
the nurses.
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